Genitourinary Cancers Symposium (ASCO GU) | Conference

Pembrolizumab Shows Promising Activity in Non-Clear Cell RCC

February 18th 2019

Single-agent pembrolizumab (Keytruda) showed encouraging antitumor activity as first-line treatment in patients with non-clear cell renal cell carcinoma, especially in those with papillary or unclassified histology.

PARP Inhibitors Hold Promise in mCRPC and Biallelic DNA Repair Gene Defects

February 18th 2019

Evan Y. Yu, MD, highlights 2 key studies with PARP inhibitors in metastatic castration-resistant prostate cancer and discussed challenges that need to be addressed in this space in order to further progress.

Dr. Siefker-Radtke on Bempegaldesleukin Plus Nivolumab in Urothelial Carcinoma

February 17th 2019

Arlene O. Siefker-Radtke, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the promise of bempegaldesleukin plus nivolumab in the treatment of patients with metastatic urothelial carcinoma.

Dr. Powles on Potential With Durvalumab in Papillary RCC

February 17th 2019

Thomas Powles, MBBS, MRCP, MD, director, Barts Cancer Institute, discusses durvalumab in combination with a MET inhibitor in the treatment of patients with papillary renal cancer.

Modest Activity With Durvalumab/Savolitinib Combo in Papillary RCC Not Enough to Warrant Further Studies

February 17th 2019

The overall response rate achieved with with the combination of savolitinib and durvalumabin in patients with metastatic papillary renal cell carcinoma in the phase II CALYPSO study did not meet the prespecified criterion for further investigation of the regimen.

Pembrolizumab/Cabozantinib Combo Is Well Tolerated, Shows Activity in Metastatic RCC

February 17th 2019

The combination of pembrolizumab (Keytruda) and cabozantinib (Cabometyx) has antitumor activity in patients with previously treated metastatic renal cell carcinoma and is tolerated at their separate approved doses for this indication.

Sacituzumab Govitecan Active in Advanced Urothelial Carcinoma

February 16th 2019

Sacituzumab govitecan exhibited significant clinical activity in an open-label, single-arm phase I/II basket study of patients with heavily pretreated, relapsed/refractory metastatic urothelial cancer.

Dr. Desai on MRI Imaging for Bone Metastases in CRPC

February 16th 2019

Arpita Desai, MD, medical oncologist, University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses the rationale for testing MRI functional imaging for bone metastases in men with castration-resistant prostate cancer.

Dr. Choueiri Discusses Avelumab/Axitinib Data in RCC

February 16th 2019

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses avelumab/axitinib data in renal cell carcinoma.

Layered Treatment With Radium-223 and Abiraterone May Reduce Skeletal Events in mCRPC

February 16th 2019

In a real-world setting, patients with metastatic castration-resistant prostate cancer who received radium-223 dichloride with abiraterone acetate in a layered fashion experienced a lower rate of symptomatic skeletal events compared with those who received the treatments concurrently.

Enzalutamide Extends Radiographic PFS in Metastatic Hormone-Sensitive Prostate Cancer

February 16th 2019

The addition of enzalutamide (Xtandi) to androgen deprivation therapy significantly prolonged radiographic progression-free survival compared with ADT alone in men with metastatic hormone-sensitive prostate cancer.

Darolutamide Improves Metastasis-Free Survival in Nonmetastatic CRPC

February 16th 2019

Darolutamide added to androgen deprivation therapy significantly improved metastasis-free survival compared with placebo plus ADT in patients with nonmetastatic castration-resistant prostate cancer enrolled in the phase III ARAMIS trial.

Dr. Balar on Rationale for KEYNOTE-057 in NMIBC

February 15th 2019

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses the rationale for the KEYNOTE-057 study in patients with non–muscle invasive bladder cancer.

Dr. Tagawa on Sacituzumab Govitecan in Urothelial Carcinoma

February 15th 2019

Scott T. Tagawa, MD, Richard A. Stratton Associate Professor in Hematology and Oncology, associate professor of clinical medicine & urology at Weill Cornell Medicine, associate attending physician, NewYork-Presbyterian–Weill Cornell Medical Center, discusses sacituzumab govitecan in the treatment of patients with urothelial carcinoma.

Nivolumab/Ipilimumab OS Benefit Sustained in Long-Term Follow-Up for Frontline RCC

February 13th 2019

Nivolumab combined with low-dose ipilimumab continued to demonstrate strong responses and a survival benefit at 30 months’ follow-up as a frontline treatment for patients with intermediate- and poor-risk advanced renal cell carcinoma.

Pembrolizumab/Axitinib Combo Improves Survival in Frontline RCC

February 12th 2019

The combination of pembrolizumab (Keytruda) and axitinib (Inlyta) was associated with a significantly longer progression-free and overall survival compared with sunitinib (Sutent) in treatment-naïve patients with clear cell metastatic renal cell carcinoma.

Hormonal Agents Induce Improved OS in African Americans With Chemo-Naive mCRPC

February 12th 2019

African-American men with metastatic castration-resistant prostate cancer treated with novel hormonal therapies—namely abiraterone acetate or enzalutamide—lived 20% longer than their Caucasian counterparts.

LuPSMA May Improve Survival in Heavily Pretreated mCRPC

February 12th 2019

The novel targeted radiation therapy lutetium-177 PSMA-617 showed strong clinical activity and the potential to improve survival in heavily pretreated men with PSMA-positive metastatic castration-resistant prostate cancer.

Pembrolizumab Plus Axitinib Active in Frontline RCC

February 12th 2018

Antitumor activity of the combination of axitinib (Inlyta) and pembrolizumab (Keytruda) is superior to that expected from axitinib or PD-1/PD-L1 pathway inhibitor monotherapy in treatment-naïve patients with advanced renal cell carcinoma.

Cabozantinib Proves Superior to Sunitinib in All Subgroups Examined in CABOSUN

February 12th 2018

Cabozantinib (Cabometyx) improved progression-free survival as initial systemic therapy across subgroups of patients with intermediate- and poor-risk advanced RCC enrolled in the randomized phase II CABOSUN trial.